CD274 and neoplasm: More importantly, the performance of tumor biomarkers in predicting ICI response is not robust enough because not all NSCLC patients with high PD-L1 expression or high TMB are responders and there are some patients with low PD-L1 or low TMB who benefitted from anti-PD1/PD-L1 therapy [62,73,74].